Derogatis Interview for Sexual Functioning

1. Abstract

The Derogatis Interview for Sexual Functioning (DISF) and its self-report counterpart, the Derogatis Interview for Sexual Functioning–Self-Report (DISF-SR), are clinician-administered and patient-reported multidimensional assessment instruments designed to quantify the quality and integrity of an individual’s current sexual functioning. Developed by Leonard R. Derogatis, the DISF operationalizes human sexuality across five fundamental domains aligned with the phases of the human sexual response cycle: Sexual Cognition/Fantasy, Sexual Arousal, Sexual Behavior/Experience, Orgasm, and Sexual Drive/Relationship. Each gender-keyed version (comprising distinct forms for men and women) contains 26 primary items measured on structured 4-point Likert-type scales, capturing both categorical frequency and qualitative intensity over a defined recall window. The instrument yields discrete item-level metrics, five functional domain scores, and an omnibus DISF Total Score. Psychometrically, the instrument demonstrates solid reliability, with internal consistency coefficients ranging from .74 to .80 across subscales, one-week test-retest reliability estimates exceeding .80, and inter-rater reliability coefficients spanning .84 to .92. Validity has been confirmed through low-to-moderate inter-domain correlations (.23 to .39) paired with substantial domain-to-total correlations (.60 to .71), substantiating that each subscale contributes unique, non-redundant variance to a coherent global construct. Criterion and predictive validity have been substantiated within urological, oncological, and psychopharmacological populations, notably demonstrating high diagnostic sensitivity (86%) and specificity (80%) in distinguishing functional, marginally functional, and dysfunctional cohorts. Standardized interpretive profiles are grounded in area t-scores derived from nonpatient community norms, enabling precise percentile-based clinical inference without distortion from non-normal distributions.

2. Keywords

Derogatis Interview for Sexual Functioning, DISF, DISF-SR, sexual dysfunction, psychometrics, sexual arousal, orgasm, sexual response cycle, area t-scores, clinical outcome assessment

3. Authors

The Derogatis Interview for Sexual Functioning was developed by Leonard R. Derogatis, Ph.D.

• Institutional Affiliations: Center for Sexual Medicine at Sheppard Pratt Health System; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
• Corporate Entity: Clinical Psychometric Research, Inc.
• Correspondence / Inquiries: Inquiries regarding licensing, scoring manuals, and research reproduction have historically been handled via Clinical Psychometric Research, Inc. and Leonard R. Derogatis (Sheppard Pratt Health System, 6501 North Charles Street, Baltimore, MD 21285; e-mail contact archived as: [email protected]).

4. Purpose

The primary clinical and psychometric purpose of the Derogatis Interview for Sexual Functioning (DISF) and its self-report edition (DISF-SR) is to establish an objective, reliable, and standardized profile of an individual’s current quality of sexual functioning across both physiological and psychological parameters. Human sexual behavior is intrinsically complex, governed by interactive neurological, vascular, endocrine, and relational dynamics. Prior to the development of the DISF, sexual medicine and clinical sexology often relied on idiosyncratic clinical interviews, single-item global self-reports, or scales that conflated physiological capability with psychological satisfaction or relationship distress. The DISF was constructed to bridge this diagnostic gap by providing a psychometrically sound, multi-tiered outcome measure suitable for both clinical practice and rigorous clinical drug trials.

The instrument is designed to serve several distinct clinical, psychotherapeutic, and empirical needs:

• Multi-Level Diagnostic Assessment: The DISF enables clinical evaluation at three hierarchical tiers: the discrete item level (e.g., morning penile tumescence, vaginal lubrication latency), the functional domain level (e.g., quantifying the arousal phase separately from orgasm), and the global summary level (the overarching DISF Total Score). This tiered architecture prevents masking phenomena, wherein a severe deficit in one isolated phase (such as anorgasmia) is obscured by high general relationship satisfaction or robust sexual interest.
• Bi-Directional Evaluation (Clinician vs. Patient vs. Partner): By providing an interviewer-administered format (DISF) alongside an almost identical self-report format (DISF-SR), clinicians can evaluate concordances and discrepancies between a clinician’s structured observation and a patient’s subjective appraisal. Furthermore, the format can be adapted for partner ratings, facilitating dyadic assessments in marital and sex therapy.
• Pharmacological and Efficacy Clinical Trials: The DISF was intentionally engineered to serve as an outcome endpoint in double-blind, placebo-controlled pharmacological trials evaluating treatments for erectile disorder, hypoactive sexual desire, female sexual arousal disorder, and psychotropic-induced sexual dysfunction (such as SSRI-induced sexual blunting). Its structure provides high sensitivity to therapeutic change while minimizing practice effects upon repeated administrations.
• Differential Profiles across Medical Illness: The scale serves oncology, cardiology, and endocrinology settings by establishing baseline measurements prior to invasive interventions (e.g., radical prostatectomy, pelvic radiation therapy, vascular reconstruction) and tracking functional recovery post-intervention.

5. Psychological Construct

The core theoretical construct operationalized by the DISF is Quality of Current Sexual Functioning. Derogatis recognized that sexual health cannot be reduced to a binary distinction between potency and impotency, nor can it be captured solely by physical genital reflexivity. Instead, sexual functioning is modeled as an integrated multidimensional behavioral system comprised of distinct psychological, neurobiological, and interactive processes. The DISF reflects this multidimensional construct through five explicitly defined functional domains, each represented by dedicated items calibrated for biological sex:

Domain I: Sexual Cognition / Fantasy

This subscale measures the cognitive, imaginative, and anticipatory components of human sexuality. It assesses the frequency, vividness, and motivational salience of erotic daydreams, sexual thoughts during waking hours, receptive sexual imagery, and mental rehearsal of sexual acts. Rather than quantifying deviant or paraphilic content, the domain captures the natural cognitive substrate that drives sexual appetite and psychogenic excitation. A deficit in this domain characterizes hyposexual conditions and psychological blunting, whereas preserved cognitive fantasy in the presence of genital impairment indicates intact central sexual drive with peripheral physiological dysfunction.

Domain II: Sexual Arousal

Domain II operationalizes the physiological and autonomic activation phases that occur in response to erotic stimulation. In the male version, items assess the frequency, firmness, and sustainability of penile erections under various contexts, including spontaneous nocturnal or morning tumescence and erections elicited during intercourse or masturbation. In the female version, the domain assesses the rapidity and extent of physiological arousal, specifically evaluating subjective awareness of pelvic vasocongestion, genital swelling, and the adequacy and duration of vaginal lubrication. Impairments in this domain point toward vasculogenic, neurogenic, hormonal, or psychogenic arousal inhibitions.

Domain III: Sexual Behavior / Experience

This subscale captures behavioral enactment, objective sexual engagement, and experiential variety over the preceding recall period (typically the past 30 days). The domain assesses the frequency of partnered sexual interactions, penetrative intercourse, manual or oral stimulation, and solitary sexual behaviors such as masturbation. It distinguishes between an individual’s desire for sexual contact and their actual physical behavioral execution, providing crucial empirical context regarding sexual opportunity, behavioral avoidance, or behavioral maintenance despite physical symptoms.

Domain IV: Orgasm

Domain IV focuses on the ejaculatory and orgasmic culmination of the sexual response cycle. Items quantify the ease, latency, subjective intensity, and consistency of reaching climax during both partnered intercourse and autoerotic activity. For male respondents, it evaluates ejaculation latency, control over climax, and the physical force or pleasure associated with seminal emission. For female respondents, it assesses clitoral and vaginal climax achievement, difficulty or delay in reaching orgasm (anorgasmia), and the perceived qualitative depth of the release. This subscale directly captures dysfunctions involving premature ejaculation, delayed ejaculation, anorgasmia, or blunted orgasmic sensation.

Domain V: Sexual Drive / Relationship

The final domain evaluates the affective, relational, and motivational context of sexual functioning. It bridges biological libido with interpersonal intimacy. Items probe the overall intensity of sexual longing, the perceived importance of sex in the respondent’s life, interpersonal affection, communication regarding sexual preferences, and reciprocal relational satisfaction. Deficits here frequently indicate dyadic friction, marital discord, or primary reductions in biological drive, providing contextual meaning to physical dysfunctions identified in other domains.

6. Theoretical Framework

The architecture of the Derogatis Interview for Sexual Functioning is theoretically rooted in the integration of physiological sexology, psychodynamic psychosomatics, and psychometric measurement theory. Primarily, the DISF operationalizes the classical physiological model formulated by William H. Masters and Virginia E. Johnson (1966) in their seminal work Human Sexual Response, along with subsequent refinements introduced by Helen Singer Kaplan (1979).

Masters and Johnson delineated human sexual response into four contiguous physiological phases: Excitement, Plateau, Orgasm, and Resolution. While groundbreaking in its physiological specificity, the Masters and Johnson four-phase model focused almost exclusively on somatic and vascular manifestations (e.g., genital vasocongestion, myotonia) and lacked explicit integration of central cognitive drive. Kaplan subsequently proposed the Triphasic Model of Sexual Response, which positioned Desire as an essential preparatory neurochemical and psychical phase preceding vascular Excitement and muscular Orgasm.

Derogatis expanded upon these paradigms by constructing an assessment model that unites neurobiological phases with behavioral and relational ecosystems. The DISF reflects this framework through the following conceptual parallels:

• Desire & Central Drive: Represented through Domain I (Sexual Cognition/Fantasy) and Domain V (Sexual Drive/Relationship), acknowledging that central nervous system appetitive drives originate in neuroendocrine pathways (dopaminergic, androgenic pathways) and are heavily modulated by cognitive-affective meaning.
• Excitement & Plateau: Represented through Domain II (Sexual Arousal), translating vascular engorgement (erection in men; lubrication, labial swelling in women) into quantifiable behavioral ratings.
• Execution: Represented through Domain III (Sexual Behavior/Experience), capturing the ecological manifestation of sexual motivation within the respondent’s life.
• Orgasm: Represented through Domain IV (Orgasm), capturing sympathetic neuromuscular discharge and the subjective hedonic experience of climax.

Furthermore, the DISF adheres strictly to modern psychometric construct validity theory as articulated by Samuel Messick (1995). Messick asserted that construct validation requires demonstrating that structural sub-dimensions within a test reflect the true dimensional structure of the underlying domain rather than artifacts of measurement method. Derogatis applied this theoretical mandate by engineering the five DISF domains to function quasi-independently: each domain demonstrates low inter-correlation with other subscales, preventing collinearity, while simultaneously demonstrating moderate-to-high correlations with the overall composite score, verifying their shared membership in the higher-order construct of general sexual quality.

7. Validity

The validity of the DISF and DISF-SR has been extensively established across diverse normative, psychiatric, and somatic medical populations through construct, convergent, discriminant, and predictive paradigms.

Construct and Structural Validity

Messick’s framework requires structural validation of subtest relations. In psychometric evaluations comprising both healthy community cohorts and clinical samples diagnosed with sexual dysfunctions, the DISF subtest intercorrelation matrices confirm the theoretical structural model. Average inter-domain correlation coefficients are intentionally low to modest (ranging from $r = .23$ to $r = .39$). This confirms that the operational definitions of each functional domain are distinct and non-redundant. Conversely, correlations between each individual functional domain and the omnibus DISF Total Score range between $r = .60$ and $r = .71$. This high domain-to-total convergence demonstrates that each subscale accounts for a substantial proportion of unique true variance while contributing validly to the global higher-order construct of sexual health.

Predictive and Criterion-Related Validity in Clinical Oncology

The clinical utility and predictive sensitivity of the DISF were demonstrated in benchmark oncology investigations by Zinreich and colleagues (1990a, 1990b) at the Johns Hopkins Oncology Center. The investigators tracked male patients diagnosed with adenocarcinoma of the prostate undergoing external beam radiation therapy:

• Diagnostic Screening Accuracy: Utilized in a logistic regression model prior to radiotherapy to identify erectile and sexual dysfunction using independent, comprehensive clinical diagnostic evaluations as the gold standard, the DISF demonstrated a sensitivity of 86%, a specificity of 80%, and a positive predictive value (PPV) of 86%.
• Post-Treatment Discriminant Validity: Following radiation therapy, patients were independently categorized via blinded clinical evaluations into three distinct functional cohorts: (a) totally functional, (b) marginally functional, and (c) fully impotent. The DISF Total Scores stratified cleanly across these categories with marked statistical significance ($p < .001$): the totally functional group obtained a mean DISF Total Score of 48.2, the marginally functional cohort averaged 21.5, and the impotent cohort dropped to 14.0. Subscale scores exhibited parallel step-wise decreases, establishing that the DISF accurately tracks progressive physiological deterioration.

Discriminant and Clinical Trial Validity

The DISF has repeatedly demonstrated discriminant validity in psychopharmacological research, particularly regarding antidepressant-induced sexual dysfunction. In clinical trials evaluating selective serotonin reuptake inhibitors (SSRIs) such as sertraline, paroxetine, and fluoxetine against atypical antidepressants such as bupropion or placebo, the DISF accurately captured phase-specific decrements. Specifically, it isolated orgasmic delay and arousal inhibition in SSRI-treated subjects while demonstrating normal baseline scores in sexual fantasy and relational satisfaction, confirming the scale’s precision in avoiding generalized, non-specific response bias.

8. Reliability

The DISF and DISF-SR have undergone rigorous testing to confirm temporal stability, inter-rater consistency, and internal scale homogeneity across clinical and community samples.

Internal Consistency

Subscale reliability analysis using Cronbach’s alpha reveals that each of the five functional subscales maintains adequate to strong internal consistency. Across normative and clinical validation samples, internal consistency coefficients for the individual domains typically range between $lpha = .74$ and $lpha = .80$. The omnibus DISF Total Score routinely achieves an internal consistency reliability coefficient exceeding $lpha = .90$. These values reflect a balanced psychometric design: items within each domain correlate sufficiently to ensure cohesive measurement of that specific functional domain without exhibiting redundant collinearity.

Test-Retest Stability

Because the DISF is designed to track treatment efficacy over time, evaluation of temporal stability in stable populations is paramount. In studies assessing non-treatment cohorts over a one-week test-retest interval, stability coefficients for all five domains were consistently observed at $r ge .80$, with several domains (notably Orgasm and Sexual Arousal) demonstrating retest coefficients exceeding $r = .85$. These findings verify that the instrument is resilient against random temporal fluctuations while remaining sensitive to true clinical shifts.

Inter-Rater Reliability

For the clinician-administered interview version (DISF), inter-rater reliability is a critical psychometric metric. Blinded simultaneous and successive co-ratings conducted by trained mental health clinicians and clinical sexologists have generated inter-rater agreement coefficients ranging between $r = .84$ and $r = .92$ across the five subscales. The structured scoring anchors and standardized interview schedule substantially reduce subjective interviewer bias.

9. Factor Analysis

The dimensional validity of the DISF is grounded in classical exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) paradigms conducted during its initial standardization and subsequent validation studies.

Factorial Structure

Factor analyses conducted on the 26 items for both the male and female instruments have confirmed a robust five-factor solution that mirrors the theoretical response cycle. When principal components analysis followed by oblique rotation (promax or oblimin) is applied, the item pool resolves into five empirical factors accounting for the majority of the total variance:

• Factor 1 (Cognition/Fantasy): Items evaluating nocturnal dreams, deliberate waking sexual thoughts, and responsiveness to environmental erotic stimuli load heavily on this factor (typical loadings ranging from .62 to .81), with negligible cross-loadings onto somatic arousal domains.
• Factor 2 (Arousal): Captures items measuring involuntary and voluntary erectile response or vaginal vasocongestion and lubricative onset. Primary factor loadings span from .58 to .84.
• Factor 3 (Behavior/Experience): Items assessing frequency of intimate contact, intercourse, manual stimulation, and partner interaction load together cleanly (loadings .54 to .76).
• Factor 4 (Orgasm): Clustered by items tapping latency to climax, frequency of climax achievement, and physical orgasmic release (loadings .65 to .88).
• Factor 5 (Drive/Relationship): Items tapping subjective desire, communication, affection, and personal value of sexual connection form an independent relational factor (loadings .52 to .79).

Higher-Order Structural Modeling

CFA investigations modeling a hierarchical structure—wherein the five first-order factors load directly onto a single, higher-order global factor representing “Overall Sexual Functioning”—demonstrate acceptable model fit indices. Confirmatory models across clinical and community cohorts routinely display goodness-of-fit indicators within conventional psychometric standards (e.g., Comparative Fit Index [CFI] $ge .92$, Root Mean Square Error of Approximation [RMSEA] $le .06$). The modest inter-factor correlations (mostly falling in the .25 to .40 range) confirm that human sexual response is fundamentally modular rather than monolithic; clinical issues can disrupt individual phases while leaving other domains functionally intact.

10. Instrument / Measurement Tool

The practical administration, scoring, and structural parameters of the Derogatis Interview for Sexual Functioning are summarized below:

• Instrument Designation: Derogatis Interview for Sexual Functioning (DISF) [Clinician-Administered Semistructured Interview]; Derogatis Interview for Sexual Functioning–Self-Report (DISF-SR) [Patient-Reported Outcome].
• Author: Leonard R. Derogatis, Ph.D.
• Primary Target Population: Adult men and women aged 18 years and older undergoing clinical screening, sex therapy, or participating in medical and clinical trial protocols.
• Item Count: 26 items per version.
• Versions / Forms: Distinct, gender-keyed forms exist for male and female respondents (DISF-M / DISF-SR-M; DISF-F / DISF-SR-F). An adapted partner-rating format can also be administered to spouses.
• Response Mode: 4-point Likert-type scales (typically structured from 0 to 3 or 1 to 4 depending on item context), capturing discrete behavioral frequencies (e.g., “Not at all” to “Frequently / Daily”) or qualitative evaluation (e.g., “None / Very Weak” to “Extremely Strong / Highly Satisfying”).
• Administration Time:
  • DISF Interview: Approximately 15 to 20 minutes for initial administration.
  • DISF-SR Self-Report: Approximately 10 to 15 minutes.
  • Subsequent Follow-ups: Administration duration typically declines substantially on repeat visits during longitudinal monitoring.
• Recall Period: Standard assessment covers the preceding thirty days (past month), providing sufficient stability against temporary daily anomalies while minimizing recall decay.
• Scoring Architecture:
  • Domain I (Sexual Cognition/Fantasy): Sum of raw scores for items 1–5.
  • Domain II (Sexual Arousal): Sum of raw scores for items 6–10.
  • Domain III (Sexual Behavior/Experience): Sum of raw scores for items 11–16.
  • Domain IV (Orgasm): Sum of raw scores for items 17–21.
  • Domain V (Sexual Drive/Relationship): Sum of raw scores for items 22–26.
  • DISF Total Score: Sum of all 26 item responses across all five functional domains.
• Standardization and Normative Conversion: Raw domain and total scores are converted to Area t-scores based on gender-stratified nonpatient community norm tables. The area transformation produces normalized distributions yielding exact percentile rank equivalencies:
  • $T = 30$: 2nd percentile (severe clinical impairment)
  • $T = 40$: 16th percentile (borderline / marginal functioning)
  • $T = 50$: 50th percentile (normative community average)
  • $T = 60$: 84th percentile (high functional capacity)
  • $T = 70$: 98th percentile (superior sexual function)
• Available Language Translations: English, French, Italian, Spanish, Dutch, Danish, and Norwegian.

11. Permissions & Fee and Test Year

The Derogatis Interview for Sexual Functioning was originally developed in the early 1990s, with formal documentation, administrative protocols, and preliminary manuals published in 1996 by Leonard R. Derogatis.

• Copyright and Commercial Distribution: The DISF and DISF-SR instruments, their scoring algorithms, user manuals, and normative profile sheets are strictly proprietary and protected by international copyright laws. They are not in the public domain and are not released as open-access psychometric tools.
• Licensing Body: The instruments are published and distributed exclusively by Clinical Psychometric Research, Inc. (formerly maintained via www.derogatis-tests.com).
• Usage Fees & Clinical Access: Researchers and clinicians wishing to implement the DISF or DISF-SR must acquire standardized testing forms, administrative manuals, and scoring licenses through Clinical Psychometric Research or authorized commercial distributors. Royalty and licensing fees are charged per administration protocol or per study participant, structured according to commercial versus academic research status. Independent clinical use requires formal authorization.

12. References

Below are primary foundational references documenting the DISF, its psychometric validation, and its clinical application:

• Derogatis, L. R. (1996). Derogatis Interview for Sexual Functioning (DISF/DISF-SR): Preliminary scoring, procedures & administration manual. Clinical Psychometric Research, Inc.
• Derogatis, L. R. (1997). The Derogatis Interview for Sexual Functioning (DISF/DISF-SR): An introduction to standard psychological measures of sexual functioning. Sexuality, Reproduction and Menopause, 2(1), 10–15.
• Kaplan, H. S. (1979). The new sex therapy: Active treatment of sexual dysfunctions. Brunner/Mazel.
• Masters, W. H., & Johnson, V. E. (1966). Human sexual response. Little, Brown and Company.
• Messick, S. (1995). Validity of psychological assessment: Validation of inferences from person’s responses and performances as scientific inquiry into score meaning. American Psychologist, 50(9), 741–749. https://doi.org/10.1037/0003-066X.50.9.741
• Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997). The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology, 49(6), 822–830. https://doi.org/10.1016/S0090-4295(97)00238-0
• Zinreich, E. S., Derogatis, L. R., Herpst, J., Auvil, G., Piantadosi, S., & Order, S. E. (1990a). Pre- and posttreatment evaluation of sexual function in patients with adenocarcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics, 19(3), 729–732. https://doi.org/10.1016/0360-3016(90)90503-4
• Zinreich, E. S., Derogatis, L. R., Herpst, J., Auvil, G., Piantadosi, S., & Order, S. E. (1990b). Pretreatment evaluation of sexual function in patients with adenocarcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics, 19(4), 1001–1004. https://doi.org/10.1016/0360-3016(90)90026-c

13. Items of the Scale